Cite
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
MLA
Wang, Zhen, et al. “Icosapent Ethyl Therapy for Very High Triglyceride Levels: A 12-Week, Multi-Center, Placebo-Controlled, Randomized, Double-Blinded, Phase III Clinical Trial in China.” Lipids in Health & Disease, vol. 22, no. 1, June 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12944-023-01838-8.
APA
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., Man, R., He, L., Wu, L., Li, Z., Shang, Y., Qiu, Z., Liu, F., Xu, C., Lai, C., & Ge, J. (2023). Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China. Lipids in Health & Disease, 22(1), 1–12. https://doi.org/10.1186/s12944-023-01838-8
Chicago
Wang, Zhen, Xin Zhang, Yanling Qu, Shuyang Zhang, Yundai Chen, Xiaoping Chen, Xin Qi, et al. 2023. “Icosapent Ethyl Therapy for Very High Triglyceride Levels: A 12-Week, Multi-Center, Placebo-Controlled, Randomized, Double-Blinded, Phase III Clinical Trial in China.” Lipids in Health & Disease 22 (1): 1–12. doi:10.1186/s12944-023-01838-8.